Healthcare

Follow Our Latest COVID-19 Updates

PHILIPPINES: FDA Updates: Use of Electronic Means of Prescription for Drugs and Registration of Drug Products under Emergency Use

With the enactment of Republic Act No. 11494, or the Bayanihan to Recover as One Act ("Bayanihan Act 2") and the periodic changes on the quarantine status of different localities, the Food and Drug Administration ("FDA") reissued and extended its existing guidelines on: (i) the implementation of the use of electronic means of prescription for drugs; and (ii) the registration of drug products under emergency use ("DEU") for COVID-19.

SINGAPORE: Telemedicine before, during and after COVID-19: Key Considerations and Issues

The acceleration in the use of telemedicine is expected to be one of the lasting changes to lifestyles as a result of the COVID-19 pandemic. As defined by the Ministry of Health (Singapore), telemedicine refers to the provision of healthcare services over physically separate environments via information technology, and it includes the exchange of information for clinical purposes between healthcare providers and patients through text messaging, web or mobile applications. In this Update, we discuss the regulatory framework in respect of telemedicine in Singapore and highlight some issues that healthcare providers, employers and patients should note in the implementation of telemedicine.

MALAYSIA: Pharmaceutical Product Registration and Cosmetic Product Notification in Malaysia

As the global COVID-19 cases continue to rise, researchers around the world are racing to understand the virus and working to roll out an effective vaccine.

In this Update, we look at the general requirements and procedure for pharmaceutical product registration and also cosmetic product notification in Malaysia.